Flamand N, Meunier J, Meunier P, Agapakis-Caussé C
L'OREAL Advanced Research, Life Sciences Research, Investigative Toxicology Department, Aulnay-Sous-Bois, France.
Toxicol In Vitro. 2001 Apr;15(2):105-14. doi: 10.1016/s0887-2333(01)00003-0.
The bacterial reverse mutagenicity test on Salmonella typhimurium, known as the Ames test, is widely used by regulatory agencies, academic institutions and chemical companies to assess the mutagenic potential of raw compounds. Several attempts have been made to miniaturise the Ames test in order to fit the industrial constraint of screening more products at the low quantities available. The major limitation of these miniaturised versions of the Ames test lies in the impossibility to work with all the six strains used in the regular Ames test, especially with those showing a low spontaneous revertant frequency. We describe here a mini version of the regulatory Ames test protocol that allows a significant reduction of the quantity of test substance needed (300 mg) but remains applicable to all Salmonella strains used in the regulatory protocol. In a preliminary study, 10 in-house chemical compounds have been evaluated in the Mini Mutagenicity Test (MMT) together with some positive control substances. A first set of historical data obtained in 1999 as well as the predictivity and the sensitivity of the MMT are presented and compared to those of the regular Ames test.
鼠伤寒沙门氏菌的细菌回复突变试验,即艾姆斯试验,被监管机构、学术机构和化工公司广泛用于评估原始化合物的致突变潜力。为了适应在可用量较少的情况下筛选更多产品的工业限制,人们已经进行了多次尝试来使艾姆斯试验小型化。这些小型化版本的艾姆斯试验的主要局限性在于无法使用常规艾姆斯试验中使用的所有六种菌株,尤其是那些自发回复突变频率较低的菌株。我们在此描述一种监管用艾姆斯试验方案的小型版本,它能显著减少所需测试物质的量(300毫克),但仍适用于监管方案中使用的所有沙门氏菌菌株。在一项初步研究中,10种内部化合物与一些阳性对照物质一起在微型致突变试验(MMT)中进行了评估。展示了1999年获得的第一组历史数据以及MMT的预测性和敏感性,并与常规艾姆斯试验的数据进行了比较。